Virtual Reality Education for Hospitalized Pediatric Patients Improves Intrinsic Motivation: A Prospective, Randomized Crossover Study.

Clin Pediatr (Phila)Jun 28, 2026 (epub)
Clinical ResearchPediatrics

Faith Collins, Emily Moya, Marcos S Rojas-Pino et al.

✦ AI-curated · Sources linked

In 30 seconds

This pragmatic, randomized crossover trial assessed the impact of bedside virtual reality (VR) education on intrinsic motivation in hospitalized pediatric patients aged 5 to 25 years. Among 100 analyzed participants, intrinsic motivation scores were significantly higher in the VR condition compared to standard of care, with a P-value of .0048. The study highlights the potential of VR as an educational tool in hospital settings.

Key findings

  • Intrinsic motivation scores were higher in the VR condition than standard of care (P = .0048).
  • Parental satisfaction with the VR education was significantly greater (P = .0008).
  • The study included 156 enrolled patients, with 100 analyzed.
  • Participants had a mean age of 11.5 years.

Why it matters

Enhancing intrinsic motivation in hospitalized children can improve their educational engagement and overall well-being during prolonged admissions. This study suggests that innovative educational methods like VR can effectively support these patients.

Source

PubMed · PMID 42366651

Published in Clin Pediatr (Phila). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.